West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes

John Hart Jr, Gail Tillman, Michael A Kraut, Hsueh-Sheng Chiang, Jeremy F Strain, Yufeng Li, Amy G Agrawal, Penny Jester, John W Gnann Jr, Richard J Whitley, NIAID Collaborative Antiviral Study Group West Nile Virus 210 Protocol Team, John Hart Jr, Gail Tillman, Michael A Kraut, Hsueh-Sheng Chiang, Jeremy F Strain, Yufeng Li, Amy G Agrawal, Penny Jester, John W Gnann Jr, Richard J Whitley, NIAID Collaborative Antiviral Study Group West Nile Virus 210 Protocol Team

Abstract

Background: West Nile Virus (WNV) is a mosquito-borne flavivirus that has caused ongoing seasonal epidemics in the United States since 1999. It is estimated that ≤1% of WNV-infected patients will develop neuroinvasive disease (West Nile encephalitis and/or myelitis) that can result in debilitating morbidities and long-term sequelae. It is essential to collect longitudinal information about the recovery process and to characterize predicative factors that may assist in therapeutic decision-making in the future.

Methods: We report a longitudinal study of the neurological outcomes (as measured by neurological examination, Glascow Coma Scale, and Modified Mini-Mental State Examination) for 55 subjects with WNV neuroinvasive disease (confirmed by positive CSF IgM) assessed on day 7, at discharge, and on days 14, 30, and 90. The neurological outcome measures were coma (presence and degree), global cognitive status, presence of cranial neuropathy, tremors and/or weakness.

Results: At initial clinical presentation 93% presented with a significant neurological deficit (49% with weakness, 35% with tremor, and 16% with cranial neuropathy). The number of patients with a cognitive deficit fell from 25 at initial evaluation to 9 at their last evaluation. Cranial neuropathy was present in 9 at onset and in only 4 patients at study conclusion. Of the 19 patients who had a tremor at enrollment, 11 continued to exhibit a tremor at follow-up. Seven patients died after initial enrollment in the study, with 5 of those having presented in a coma. The factors that predict either severity or long-term recovery of neurological function include age (older individuals were weaker at follow-up examination), gender (males recovered better from coma), and presentation in a coma with cranial nerve deficits (had a poorer recovery particularly with regard to cognition).

Conclusions: This study represents one of the largest clinical investigations providing prospectively-acquired neurological outcomes data among American patients with WNV central nervous system disease. The findings show that the factors that influence prognosis from the initial presentation include age, gender, and specific neurological deficits at onset.

Trial registration: ClinicalTrials.gov identifier: NCT00138463 and NCT00069316.

References

    1. Davis LE, DeBiasi R, Goade DE, Haaland KY, Harrington JA, Harnar JB, Pergam SA, King MK, DeMasters BK, Tyler KL. West Nile virus neuroinvasive disease. Ann Neurol. 2006;14:286–300. doi: 10.1002/ana.20959.
    1. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;14:181–194. doi: 10.1146/annurev.med.57.121304.131418.
    1. Nash D, Mostashari F, Fine A, Miller J, O’Leary D, Murray K, Huang A, Rosenberg A, Greenberg A, Sherman M, Wong S, Layton M. West Nile Outbreak Response Working Group. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 1999;14(344):1807–1814.
    1. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;14:1617–1624. doi: 10.1086/518281.
    1. Busch MP, Wright DJ, Custer B, Tobler LH, Stramer SL, Kleinman SH, Prince HE, Bianco C, Foster G, Petersen LR, Nemo G, Glynn SA. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis. 2006;14:395–402. doi: 10.3201/eid1205.051287.
    1. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. West Nile encephalitis epidemic in southeastern Romania. Lancet. 1998;14:767–771. doi: 10.1016/S0140-6736(98)03538-7.
    1. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ, Katz N, Liljebjelke KA, Biggerstaff BJ, Fine AD, Layton MC, Mullin SM, Johnson AJ, Martin DA, Hayes EB, Campbell GL. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;14:261–264. doi: 10.1016/S0140-6736(01)05480-0.
    1. Debiasi RL, Tyler KL. West Nile virus meningoencephalitis. Nat Clin Pract Neurol. 2006;14:264–275. doi: 10.1038/ncpneuro0176.
    1. Sejvar JJ. Clinical manifestations and outcomes of West Nile Virus Infection. Viruses. 2014;14:606–623. doi: 10.3390/v6020606.
    1. Cao NJ, Ranganathan C, Kupsky WJ, Li J. Recovery and prognosticators of paralysis in West Nile virus infection. J Neurol Sci. 2005;14:73–80. doi: 10.1016/j.jns.2005.05.007.
    1. Schafernak KT, Bigio EH. West Nile virus encephalomyelitis with polio-like paralysis & nigral degeneration. Can J Neurol Sci. 2006;14:407–410.
    1. Burton JM, Kern RZ, Halliday W, Mikulis D, Brunton J, Fearon M, Pepperell C, Jaigobin C. Neurological manifestations of West Nile virus infection. Can J Neurol Sci. 2004;14:185–193.
    1. Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Ewing D, Mazowiecki M, Pavot PV, Schmitt J, Pape J, Biggerstaff BJ, Petersen LR. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;14:1021–1027. doi: 10.3201/eid1107.040991.
    1. Bhangoo S, Chua R, Hammond C, Kimmel Z, Semenov I, Videnovic A, Kessler J, Borsody M. Focal neurological injury caused by West Nile virus infection may occur independent of patient age and premorbid health. J Neurol Sci. 2005;14:93–98. doi: 10.1016/j.jns.2005.03.041.
    1. Watson NK, Bartt RE, Houff SA, Leurgans SE, Schneck MJ. Focal neurological deficits and West Nile virus infection. Clin Infect Dis. 2005;14:e59–e62. doi: 10.1086/428117.
    1. Sejvar JJ, Leis AA, Stokic DS, Van Gerpen JA, Marfin AA, Webb R, Haddad MB, Tierney BC, Slavinski SA, Polk JL, Dostrow V, Winkelmann M, Petersen LR. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis. 2003;14:788–793. doi: 10.3201/eid0907.030129.
    1. Saad M, Youssef S, Kirschke D, Shubair M, Haddadin D, Myers J, Moorman J. Acute flaccid paralysis: the spectrum of a newly recognized complication of West Nile virus infection. J Infect. 2005;14:120–127. doi: 10.1016/j.jinf.2004.10.005.
    1. Leis AA, Stokic DS, Polk JL, Dostrow V, Winkelmann M. A poliomyelitis-like syndrome from West Nile virus infection. N Engl J Med. 2002;14:1279–1280. doi: 10.1056/NEJM2002c021587.
    1. Petropoulou KA, Gordon SM, Prayson RA, Ruggierri PM. West Nile virus meningo- encephalitis: MR imaging findings. Am J Neuroradiol. 2005;14:1986–1995.
    1. Robertson HJ, Sejvar JJ. The need for a West Nile virus MRI registry. Am J Neuroradiol. 2003;14:1741–1742.
    1. Ali M, Safriel Y, Sohi J, Llave A, Weathers S. West Nile virus infection: MR imaging findings in the nervous system. Am J Neuroradiol. 2005;14:289–297.
    1. Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Pape J, Biggerstaff BJ, Petersen LR. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;14:514–516. doi: 10.3201/eid1203.050643.
    1. Bode AV, Sejvar JJ, Pape WJ, Campbell GL, Marfin AA. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis. 2006;14:1234–1240. doi: 10.1086/503038.
    1. Carson PJ, Konewko P, Wold KS, Mariani P, Goli S, Bergloff P, Crosby RD. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis. 2006;14:723–730. doi: 10.1086/506939.
    1. Klee AL, Maidin B, Edwin B, Poshni I, Mostashari F, Fine A, Layton M, Nash D. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis. 2004;14:1405–1411. doi: 10.3201/eid1008.030879.
    1. Marciniak C, Sorosky S, Hynes C. Acute flaccid paralysis associated with West Nile virus: motor and functional improvement in 4 patients. Arch Phys Med Rehabil. 2004;14:1933–1938. doi: 10.1016/j.apmr.2004.04.038.
    1. Tombaugh TN. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. Arch Clin Neuropsychol. 2005;14:485–503. doi: 10.1016/j.acn.2004.11.004.
    1. Bodian D. An electron-microscopic study of the monkey spinal cord. I. Fine structure of normal motor column. II. Effects of retrograde chromatolysis. III. Cytologic effects of mild and virulent poliovirus infection. Bull Johns Hopkins Hosp. 1964;14:13–119.
    1. Ware J, Snow K, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: Health Institute, New England Medical Center; 1993.
    1. Loeb M, Hanna S, Nicolle L, Eyles J, Elliott S, Rathbone M, Drebot M, Neupane B, Fearon M, Mahony J. Prognosis after West Nile virus infection. Ann Intern Med. 2008;14:232–241. doi: 10.7326/0003-4819-149-4-200808190-00004.
    1. Cook RL, Xu X, Yablonsky EJ, Sakata N, Tripp JH, Hess R, Piazza P, Rinaldo CR. Demographic and clinical factors associated with persistent symptoms after West Nile virus infections. Am J Trop Med Hyg. 2010;14:1133–1136. doi: 10.4269/ajtmh.2010.09-0717.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren